WANG Yong-sheng. The Bispecific T-Cell Engager Tarlatamab Made a Breakthrough in Extensive Stage Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 21-22. DOI: 10.12019/j.issn.1671-5144.202502005
|
Citation:
|
WANG Yong-sheng. The Bispecific T-Cell Engager Tarlatamab Made a Breakthrough in Extensive Stage Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 21-22. DOI: 10.12019/j.issn.1671-5144.202502005
|
WANG Yong-sheng. The Bispecific T-Cell Engager Tarlatamab Made a Breakthrough in Extensive Stage Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 21-22. DOI: 10.12019/j.issn.1671-5144.202502005
|
Citation:
|
WANG Yong-sheng. The Bispecific T-Cell Engager Tarlatamab Made a Breakthrough in Extensive Stage Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 21-22. DOI: 10.12019/j.issn.1671-5144.202502005
|
DownLoad: